top of page

SCIB1 continues to deliver encouraging survival data in melanoma

Scancell has provided an update from the SCIB1 Phase I/II clinical trial in malignant melanoma, the lead programme from the Company’s ImmunoBody platform.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page